Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma

医学 肝细胞癌 实体瘤疗效评价标准 放射外科 肝硬化 完全响应 放射科 核医学 放射治疗 临床试验 内科学 临床研究阶段 化疗
作者
Trevor R. P. Price,Susan M. Perkins,Kumaresan Sandrasegaran,M. Henderson,Mary A. Maluccio,Jennifer Zook,A. Joseph Tector,Rodrigo Vianna,Peter A.S. Johnstone,Higinia R. Cárdenes
出处
期刊:Cancer [Wiley]
卷期号:118 (12): 3191-3198 被引量:134
标识
DOI:10.1002/cncr.26404
摘要

Hepatocellular carcinoma (HCC) is increasing in incidence due to hepatitis C. Stereotactic body radiotherapy (SBRT) is a noninvasive, effective therapy in the management of liver malignancies. The authors evaluated radiological response in 26 patients with HCC treated with SBRT at Indiana University.Between March 2005 and June 2008, 26 patients with HCC who were not surgical candidates were enrolled in a phase 1 to 2 trial. Eligibility criteria included solitary tumors ≤ 6 cm or up to 3 lesions with sum diameters ≤ 6 cm, and well-compensated cirrhosis. All patients had imaging before, at 1 to 3 months, and every 3 to 6 months after SBRT.Patients received 3 to 5 fractions of SBRT. Median SBRT dose was 42 Gray (Gy) (range: 24-48 Gy). Median follow-up was 13 months. Per Response Evaluation Criteria in Solid Tumors (RECIST), 4 patients had a complete response (CR), 15 had a partial response (PR), and 7 achieved stable disease (SD) at 12 months. One patient with SD experienced progression marginal to the treated area. The overall best response rate (CR + PR) was 73%. In comparison, by European Association for the Study of the Liver (EASL) criteria, 18 of 26 patients had ≥ 50% nonenhancement at 12 months. Thirteen of 18 demonstrated 100% nonenhancement, being > 50% in 5 patients. Kaplan-Meier 1- and 2-year survival estimates were 77% and 60%, respectively.SBRT is effective therapy for patients with HCC with an overall best response rate (CR + PR) of 73%. Nonenhancement on imaging, a surrogate for ablation, may be a more useful indicator than size reduction in evaluating HCC response to SBRT in the first 6 to 12 months, supporting EASL criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
弧光完成签到 ,获得积分0
4秒前
dmm完成签到 ,获得积分10
5秒前
佳期如梦完成签到 ,获得积分10
7秒前
展会恩完成签到,获得积分10
7秒前
干将莫邪完成签到,获得积分10
8秒前
执着夏岚完成签到 ,获得积分10
11秒前
11秒前
14秒前
lhn完成签到 ,获得积分10
14秒前
饱满烙完成签到 ,获得积分10
15秒前
菓小柒完成签到 ,获得积分10
15秒前
17秒前
18秒前
hongxing liu发布了新的文献求助10
23秒前
Dongjie发布了新的文献求助10
25秒前
杨永佳666完成签到 ,获得积分10
26秒前
Lisztan完成签到,获得积分10
29秒前
Tysonqu完成签到,获得积分10
29秒前
萤火虫完成签到,获得积分10
30秒前
饱满的新之完成签到 ,获得积分10
32秒前
songyu完成签到,获得积分10
33秒前
33秒前
黑苹果完成签到,获得积分10
35秒前
孙总完成签到,获得积分10
36秒前
健壮仙人掌完成签到,获得积分10
39秒前
鲸鱼打滚完成签到 ,获得积分10
40秒前
传奇3应助科研通管家采纳,获得10
43秒前
hongxing liu完成签到,获得积分10
45秒前
紫金之巅完成签到 ,获得积分10
46秒前
快乐的90后fjk完成签到 ,获得积分10
47秒前
漂亮的忆文完成签到,获得积分10
51秒前
蜗牛完成签到 ,获得积分10
53秒前
科研通AI2S应助hongxing liu采纳,获得10
56秒前
haochi完成签到,获得积分10
59秒前
Gavin完成签到,获得积分10
59秒前
fatcat完成签到,获得积分10
1分钟前
qianci2009完成签到,获得积分10
1分钟前
徐旖旎完成签到,获得积分10
1分钟前
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167370
捐赠科研通 3248804
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664